The glucagon receptor activation changes how your body processes dietary fat, and combining that with the gastric slowing from GLP-1 agonism creates a perfect storm for nausea
Unlike standard panels that only report static values, CTI applies a logarithmic formula to quantify combined metabolic and inflammatory risk
And, in patients with PAD, these new data provide robust evidence that semaglutide is a therapy to improve their function, quality of life, and progression of disease. The study authors indicate that further research is warranted to understand whether these benefits extend to individuals with PAD who do not have diabetes.
Therefore, the choice of clinical treatment needs to be weighed against a variety of factors, including efficacy, safety, and individual patient differences, to develop a better treatment plan for subsequent diagnosis and treatment
Nutr Rev 70(9):509519 Marshall JS et al (2018) An introduction to immunology and immunopathology